Tandem haematopoietic stem cell transplantation versus single cell transplant and BV maintenance in relapsed/refractory Hodgkin lymphoma: A matched cohort analysis from the LYSA.
Amira MaroufN MolinariDavid SibonA S CottereauS KanounC AntoineP E DebureauxD CavalieriL M ForneckerR O CasasnovasCharles HerbauxS AmorimCédric RossiD BouscaryP BriceHervé GhesquièresJ TamburiniBenedicte DeauPublished in: British journal of haematology (2023)
Autologous hematopoietic stem cell transplant (ASCT) is the standard curative treatment for patients with high-risk relapsed/refractory Hodgkin lymphoma (R/R HL). The AETHERA study showed survival gain with Brentuximab Vedotin (BV) maintenance after ASCT in BV-naive patients, which was recently confirmed in the retrospective AMAHRELIS cohort, including a majority of BV-exposed patients. However, this approach has not been compared to intensive tandem auto/auto or auto/allo transplant strategies, which were used before BV approval. Here, we matched BV maintenance (AMAHRELIS) and tandem SCT (HR2009) cohorts, and observed that BV maintenance was associated with better survival outcome in patients with HR R/R HL.
Keyphrases
- hodgkin lymphoma
- lps induced
- lipopolysaccharide induced
- end stage renal disease
- stem cell transplantation
- chronic kidney disease
- newly diagnosed
- inflammatory response
- acute myeloid leukemia
- high dose
- acute lymphoblastic leukemia
- stem cells
- low dose
- bone marrow
- diffuse large b cell lymphoma
- peritoneal dialysis
- hematopoietic stem cell
- combination therapy
- cross sectional
- patient reported